Sanofi and AstraZeneca win US approval for RSV vaccine for infants
Sanofi and AstraZeneca announced on Monday that they have received approval from the US Food and Drug Administration (FDA) for a vaccine, Beyfortus, against respiratory syncytial virus (RSV) for use in newborns and infants. The approval covers children up to 24 months of age.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
UK approves RSV vaccine from GSK
For subscribers
Moderna seeks approval in Europe and the US for RSV vaccine
For subscribers
Pfizer, GSK shots for RSV get backing for older adults
For subscribers